Semaglutide cuts major heart events, but researchers still cannot fully explain why

https://www.news-medical.net/news/20260927/Semaglutide-cuts-major-heart-events-but-researchers-still-cannot-fully-explain-why.aspx A detailed analysis of the SELECT trial examined how much of the reduction in major heart events could be attributed to changes in weight, inflammation, blood glucose, and other cardiovascular risk factors. In a recent study published in the European Heart Journal, researchers investigated which measured cardiovascular risk factors might help explain semaglutide's cardioprotective effects. The study comprised a pre-specified mediation analysis of the landmark SELECT trial, which evaluated 17,604 adults with overweight or obesity and established cardiovascular disease (CVD) without diabetes. Its primary objective was to estimate how much of the drug’s benefit could be explained by improvements in traditional risk factors.